| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester are not biological targets but rather chemical reaction partners in organic synthesis. As a boronic ester, it serves as a nucleophilic coupling partner in Suzuki-Miyaura cross-coupling reactions with various aryl or vinyl halides. The Cbz protecting group provides stability and allows for selective deprotection under hydrogenation conditions. The compound is used as a building block for the synthesis of pharmaceutically relevant molecules.
|
|---|---|
| ln Vitro |
In vitro activity for N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester refers to its chemical reactivity rather than biological activity. The compound demonstrates utility as a nucleophilic coupling partner in Suzuki-Miyaura cross-coupling reactions. Its reactivity is enhanced by the boronic ester functional group, which participates in transmetallation reactions with palladium catalysts. The tetrahydropyridine ring provides a scaffold for further functionalization in synthetic sequences.
|
| ln Vivo |
In vivo activity data are not applicable for N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester, as it is a chemical reagent rather than a pharmacologically active compound. The compound is not intended for biological or therapeutic applications. Its use is limited to organic synthesis and medicinal chemistry as a building block for the preparation of more complex molecules.
|
| Enzyme Assay |
Non-cellular assays for N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester typically involve characterization of its chemical properties and purity. Standard analytical techniques include NMR spectroscopy, HPLC, and mass spectrometry to confirm identity and purity. The compound's reactivity in Suzuki-Miyaura cross-coupling reactions is assessed by monitoring reaction progress using TLC or HPLC. Solubility testing is performed in common organic solvents for synthetic applications.
|
| Cell Assay |
Cellular assays are not applicable for N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester, as it is a chemical reagent not intended for cell-based studies. The compound is used in organic synthesis and drug discovery as a building block, but it is not studied for biological activity in cell culture systems. Its use is limited to chemical reactions outside of living systems.
|
| Animal Protocol |
In vivo animal experiments are not conducted for N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester, as it is a chemical reagent rather than a therapeutic or pharmacological compound. The compound is not administered to animals for any research purpose. Its applications are strictly limited to synthetic chemistry and medicinal chemistry as a reagent or building block.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester, as it is a chemical reagent and not a pharmaceutical compound. The compound's molecular weight and physicochemical properties are relevant for its use in organic synthesis. Solubility information and stability data are available from chemical suppliers for synthetic chemistry applications.
|
| Toxicity/Toxicokinetics |
Standard laboratory safety precautions should be followed when handling N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester. As with all chemical reagents, it may be irritating to skin, eyes, and respiratory tract. Appropriate personal protective equipment should be worn when handling the compound. The compound should be stored in a cool, dry place away from incompatible materials. Consult the safety data sheet for detailed safety information.
|
| Additional Infomation |
Other information includes the compound's use as a synthetic building block in organic chemistry and drug discovery. It is commonly used in Suzuki-Miyaura cross-coupling reactions to introduce the tetrahydropyridine moiety into target molecules. The Cbz protecting group allows for selective deprotection under hydrogenation conditions, enabling further functionalization. The compound is valuable for the synthesis of pharmaceutical intermediates and natural product analogs.
|
| Molecular Formula |
C19H26BNO4
|
|---|---|
| Molecular Weight |
343.23
|
| Exact Mass |
343.195
|
| CAS # |
286961-15-7
|
| PubChem CID |
11290836
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
418.2±55.0 °C at 760 mmHg
|
| Melting Point |
88-90℃
|
| Flash Point |
206.7±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
3.524
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
510
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N1CCC(B2OC(C)(C)C(C)(C)O2)=CC1)OCC3=CC=CC=C3
|
| InChi Key |
QDSFHRPYZPQWEJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H26BNO4/c1-18(2)19(3,4)25-20(24-18)16-10-12-21(13-11-16)17(22)23-14-15-8-6-5-7-9-15/h5-10H,11-14H2,1-4H3
|
| Chemical Name |
benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 18 mg/mL (52.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9135 mL | 14.5675 mL | 29.1350 mL | |
| 5 mM | 0.5827 mL | 2.9135 mL | 5.8270 mL | |
| 10 mM | 0.2913 mL | 1.4567 mL | 2.9135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
